title: A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial.
abstract: Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conducted to assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130 mg/m(2) on day 1 and prednisone 100 mg/day on days 1-5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range = 27-74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate = 64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI = 2.1-26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392).
authors.affiliation: a Department of Internal Medicine , Dong-A University Hospital , Busan , Korea ;
authors.forename: Sung Yong
authors.initials: SY
authors.lastname: Oh
authors.affiliation: b Department of Medicine , Samsung Medical Center, Sunkyunkwan University School of Medicine , Soeul , Korea ;
authors.forename: Won Seog
authors.initials: WS
authors.lastname: Kim
authors.affiliation: c Division of Hematology, Department of Internal Medicine , Yonsei University College of Medicine , Korea ;
authors.forename: Jin Seok
authors.initials: JS
authors.lastname: Kim
authors.affiliation: d Department of Oncology/Hematology , Kyungpook National University Medical Center, Kyungpook National University School of Medicine , Korea ;
authors.forename: Yee Soo
authors.initials: YS
authors.lastname: Chae
authors.affiliation: e Division of Hematology-Oncology, Department of Internal Medicine , Gyeongsang National University Hospital, Gyeongsang National University School of Medicine , Korea ;
authors.forename: Gyeong-Won
authors.initials: GW
authors.lastname: Lee
authors.affiliation: f Department of Hematologic-Oncology , Research Institute & Hospital, National Cancer Center , Korea ;
authors.forename: Hyeon Seok
authors.initials: HS
authors.lastname: Eom
authors.affiliation: g Department of Internal Medicine , Daegu Catholic University Medical Center , Korea ;
authors.forename: Hun Mo
authors.initials: HM
authors.lastname: Ryoo
authors.affiliation: a Department of Internal Medicine , Dong-A University Hospital , Busan , Korea ;
authors.forename: Suee
authors.initials: S
authors.lastname: Lee
authors.affiliation: b Department of Medicine , Samsung Medical Center, Sunkyunkwan University School of Medicine , Soeul , Korea ;
authors.forename: Seok Jin
authors.initials: SJ
authors.lastname: Kim
authors.affiliation: h Department of Oncology , Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea ;
authors.forename: Dok Hyun
authors.initials: DH
authors.lastname: Yoon
authors.affiliation: i Department of Internal Medicine , Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine , Korea ;
authors.forename: Jong Ho
authors.initials: JH
authors.lastname: Won
authors.affiliation: j Division of Hematology and Oncology, Department of Internal Medicine , Gachon University Gil Medical Center , Incheon , Korea ;
authors.forename: Junshik
authors.initials: J
authors.lastname: Hong
authors.affiliation: j Division of Hematology and Oncology, Department of Internal Medicine , Gachon University Gil Medical Center , Incheon , Korea ;
authors.forename: Jinny
authors.initials: J
authors.lastname: Park
authors.affiliation: k Department of Hemato/Oncology , Busan Paik Hospital, College of Medicine, Inje University , Busan , Korea ;
authors.forename: Sang-Min
authors.initials: SM
authors.lastname: Lee
authors.affiliation: l Division of Hemato-Oncology, Department of Internal Medicine , Chung-Ang University College of Medicine , Korea ;
authors.forename: Jung Yong
authors.initials: JY
authors.lastname: Hong
authors.affiliation: l Division of Hemato-Oncology, Department of Internal Medicine , Chung-Ang University College of Medicine , Korea ;
authors.forename: Eunkyung
authors.initials: E
authors.lastname: Park
authors.affiliation: m Department of Internal Medicine , Hallym University Sacred Heart Hospital, Hallym University College of Medicine , Korea ;
authors.forename: Hyo Jung
authors.initials: HJ
authors.lastname: Kim
authors.affiliation: n Department of Hematology-Oncology , Chonnam National University Hwasun Hospital , Jeollanam-do , Korea.
authors.forename: Deok-Hwan
authors.initials: DH
authors.lastname: Yang
authors.affiliation: a Department of Internal Medicine , Dong-A University Hospital , Busan , Korea ;
authors.forename: Hyo-Jin
authors.initials: HJ
authors.lastname: Kim
authors.affiliation: h Department of Oncology , Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea ;
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012008:Recurrence; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D011241:Prednisone
keywords: Oxaliplatin; marginal zone lymphoma; prednisone; refractory; relapse